Pirarubicin

DB11616InvestigationalSmall molecule

Pirarubicin: Overview.

Chemical structure of Pirarubicin
Mechanism
Curator reviewed
Formula / weight
C32H37NO12 · 627.643 g/mol (avg)
Also known as
Theprubicin · THP-Adm · THP-Doxorubicin

Resolves to

Compound
UNIID58G680W0GCAS72496-41-4ChEMBLCHEMBL2354444ChEBI94770PubChem11296583KEGGD01885
Clinical / RWD
RxNorm33764ATCL01DB08
Structure
InChIKeyKMSKQZKKOZQFFG-YXRRJAAWSA-NSMILES[H][C@]1(N)C[C@]([H])(O[C@@]2([H])C[C@@](O)(CC3=C(O)C4=C(C(O)=C23)C(=O)C2=C(C=CC=C2OC)C4=O)C(=O)CO)O[C@@]([H])(C)[C@@]1([H])O[C@]1([H])CCCCO1
Transporters
P33527ABCC1P08183ABCB1Q9UNQ0ABCG2O43868SLC28A2

What you can answer from here — as of August 30, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4TransportersSubstrate / inhibitor direction, not just membership
Listed above
400Drug interactionsStructured to mechanism, not free text
Sign in
33Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1ATC codeIncluding every combination product, plus 12 drug categories
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of Pirarubicin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In